Antibody Drug Conjugates Market Driven by
Extensive Research and Development Activities Top
Players Are Hoffmann-La Roche Ltd, , GE
Healthcare
Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad
therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to
mark and kill only cancer cells. Antibody drug conjugates are compound molecules that
comprise antibodies linked to a biologically active cytotoxic drug.
Request Sample Copy of Research Report @ https://bit.ly/2GYVBLB
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for
subtle judgment between healthy and diseased tissue. This entails that the antibody drug
conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected.
This exceptional phenomenon of killing only cancer cells increase the importance of use of
ADCs, which would indirectly boost growth of the global antibody drug conjugates market.
Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to
over US$ 10 billion over the forecast period of market
In terms of marketing, three antibody drug conjugates have received regulatory approval. The
U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to
treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving
only two antibody drug conjugates in the market. The two drugs marketed for ADCs are
Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle
Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody
drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a
high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development.
Frequently used cytotoxins for antibody drug conjugates under trials include auristatin,
calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting
for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds
under clinical trials, and this is the most developed pipeline of antibody drug conjugates.
Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There
are limited number of contract manufacturers that have high-end manufacturing equipment for
development of cytotoxins.